28078640|t|Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods
28078640|a|Health-related quality of life (HRQOL) is arguably one of the most important measures in evaluating effectiveness of clinical treatments. At present, there is no disease - specific outcome measure to assess the HRQOL of children, adolescents and young adults with Neurofibromatosis Type 1 (NF1). This study aimed to develop the items and support the content validity for the Pediatric Quality of Life Inventory™ (PedsQL™) NF1 Module for children, adolescents and young adults. The iterative process included multiphase qualitative methods including a literature review, survey of expert opinions, semi-structured interviews, cognitive interviews and pilot testing. Fifteen domains were derived from the qualitative methods, with content saturation achieved, resulting in 115 items. The domains include skin, pain, pain impact, pain management, cognitive functioning, speech, fine motor, balance, vision, perceived physical appearance, communication, worry, treatment, medicines and gastrointestinal symptoms. This study is limited because all participants are recruited from a single - site. Qualitative methods support the content validity for the PedsQL™ NF1 Module for children, adolescents and young adults. The PedsQL™ NF1 Module is now undergoing national multisite field testing for the psychometric validation of the instrument development.
28078640	0	11	Development	T169	C1527148
28078640	19	54	pediatric quality of life inventory	T170	C2698752
28078640	55	79	neurofibromatosis type 1	T191	C0027831
28078640	80	86	module	T170	C3542953
28078640	87	92	items	T062,T170	C0871509
28078640	97	105	children	T100	C0008059
28078640	107	118	adolescents	T100	C0205653
28078640	123	135	young adults	T100	C0238598
28078640	137	156	qualitative methods	T062	C0681940
28078640	157	187	Health-related quality of life	T078	C4279947
28078640	189	194	HRQOL	T078	C4279947
28078640	224	233	important	T080	C3898777
28078640	234	242	measures	T081	C0079809
28078640	246	256	evaluating	T058	C0220825
28078640	257	270	effectiveness	T080	C1280519
28078640	274	293	clinical treatments	T061	C1516635
28078640	319	326	disease	T047	C0012634
28078640	329	337	specific	T080	C0205369
28078640	338	353	outcome measure	T081	C0086749
28078640	357	363	assess	T058	C0184514
28078640	368	373	HRQOL	T078	C4279947
28078640	377	385	children	T100	C0008059
28078640	387	398	adolescents	T100	C0205653
28078640	403	415	young adults	T100	C0238598
28078640	421	445	Neurofibromatosis Type 1	T191	C0027831
28078640	447	450	NF1	T191	C0027831
28078640	458	463	study	T062	C2603343
28078640	485	490	items	T062,T170	C0871509
28078640	507	523	content validity	T080	C1510592
28078640	532	568	Pediatric Quality of Life Inventory™	T170	C2698752
28078640	570	577	PedsQL™	T170	C2698752
28078640	579	582	NF1	T191	C0027831
28078640	583	589	Module	T170	C3542953
28078640	594	602	children	T100	C0008059
28078640	604	615	adolescents	T100	C0205653
28078640	620	632	young adults	T100	C0238598
28078640	638	647	iterative	T033	C1854293
28078640	648	655	process	T067	C1522240
28078640	665	695	multiphase qualitative methods	T062	C0681940
28078640	708	725	literature review	T170	C0282441
28078640	727	733	survey	T170	C0038951
28078640	737	752	expert opinions	T077	C0600219
28078640	754	780	semi-structured interviews	T052	C0021822
28078640	782	791	cognitive	T169	C1516691
28078640	792	802	interviews	T052	C0021822
28078640	807	820	pilot testing	T062	C0031928
28078640	830	837	domains	T169	C1880389
28078640	860	879	qualitative methods	T062	C0681940
28078640	886	893	content	T077	C0456205
28078640	932	937	items	T062,T170	C0871509
28078640	943	950	domains	T169	C1880389
28078640	959	963	skin	T022	C1123023
28078640	965	969	pain	T184	C0030193
28078640	971	975	pain	T184	C0030193
28078640	976	982	impact	T080	C4049986
28078640	984	999	pain management	T061	C0002766
28078640	1001	1022	cognitive functioning	T041	C0392335
28078640	1024	1030	speech	T040	C0037817
28078640	1032	1042	fine motor	T042	C0678857
28078640	1044	1051	balance	T169	C0205415
28078640	1053	1059	vision	T040	C0042789
28078640	1061	1070	perceived	T041	C0030971
28078640	1071	1090	physical appearance	T184	C0750731
28078640	1092	1105	communication	T054	C0009452
28078640	1107	1112	worry	T033	C0233481
28078640	1114	1123	treatment	T061	C0087111
28078640	1125	1134	medicines	T121	C0013227
28078640	1139	1164	gastrointestinal symptoms	T184	C0426576
28078640	1180	1187	limited	T169	C0439801
28078640	1200	1212	participants	T098	C0679646
28078640	1234	1240	single	T081	C0205171
28078640	1243	1247	site	T082	C0205145
28078640	1249	1268	Qualitative methods	T062	C0681940
28078640	1281	1297	content validity	T080	C1510592
28078640	1306	1313	PedsQL™	T170	C2698752
28078640	1314	1317	NF1	T191	C0027831
28078640	1318	1324	Module	T170	C3542953
28078640	1329	1337	children	T100	C0008059
28078640	1339	1350	adolescents	T100	C0205653
28078640	1355	1367	young adults	T100	C0238598
28078640	1373	1380	PedsQL™	T170	C2698752
28078640	1381	1384	NF1	T191	C0027831
28078640	1385	1391	Module	T170	C3542953
28078640	1410	1442	national multisite field testing	T169	C0039593
28078640	1451	1463	psychometric	T060	C0033920
28078640	1464	1474	validation	T062	C1519941
28078640	1482	1492	instrument	T170	C0038951
28078640	1493	1504	development	T169	C1527148